{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:05:22Z","timestamp":1790283922539,"version":"4.1.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Microbe"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.lanmic.2025.101266","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T12:16:28Z","timestamp":1766578588000},"page":"101266","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Strengthening hepatitis B virus clinical research in Africa: the need for multistakeholder collaboration, funding, and political will"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-7887-4815","authenticated-orcid":false,"given":"Mitchell","family":"Leus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chukwunomso E","family":"Osakwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danjuma","family":"Adda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manal","family":"El-Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Hicks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4036-4269","authenticated-orcid":false,"given":"Philippa C","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicaise","family":"Ndembi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theobald","family":"Owusu-Ansah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine Wendy","family":"Spearman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark W","family":"Sonderup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4733-4692","authenticated-orcid":false,"given":"Robin","family":"Schaefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lanmic.2025.101266_bib3","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2468-1253(23)00315-1","article-title":"Under-representation of the WHO African region in clinical trials of interventions against hepatitis B virus infection","volume":"9","author":"Delphin","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.lanmic.2025.101266_bib4","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000360947","article-title":"Genotypes and genetic variability of hepatitis B virus","volume":"57","author":"Kramvis","year":"2014","journal-title":"Intervirology"},{"key":"10.1016\/j.lanmic.2025.101266_bib5","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa2407001","article-title":"Twice-yearly lenacapavir or daily F\/TAF for HIV prevention in cisgender women","volume":"391","author":"Bekker","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanmic.2025.101266_bib6","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(23)02511-4","article-title":"Safety and efficacy of malaria vaccine candidate R21\/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial","volume":"403","author":"Datoo","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.lanmic.2025.101266_bib7","doi-asserted-by":"crossref","first-page":"8662","DOI":"10.1038\/s41467-024-53126-3","article-title":"Strengthening and expanding capacities in clinical trials: advancing pandemic prevention, preparedness and response in Africa","volume":"15","author":"Ndembi","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.lanmic.2025.101266_bib8","article-title":"HBV elimination in Africa\u2014current status and challenges","volume":"23","author":"Sonderup","year":"2024","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"10.1016\/j.lanmic.2025.101266_bib9","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70051","article-title":"Twenty-five years of addressing cutting-edge scientific, policy, and regulatory issues through collaboration: the Forum for Collaborative Research","volume":"17","author":"Schaefer","year":"2024","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.lanmic.2025.101266_bib10","first-page":"17","article-title":"Molecular characteristics and clinical relevance of African genotypes and subgenotypes of hepatitis B virus","volume":"108","author":"Kramvis","year":"2018","journal-title":"S Afr Med J"},{"key":"10.1016\/j.lanmic.2025.101266_bib11","doi-asserted-by":"crossref","first-page":"513","DOI":"10.3851\/IMP2657","article-title":"Subgenotype A1 of HBV\u2013tracing human migrations in and out of Africa","volume":"18","author":"Kramvis","year":"2013","journal-title":"Antivir Ther"},{"key":"10.1016\/j.lanmic.2025.101266_bib12","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1111\/j.1872-034X.2007.00098.x","article-title":"Epidemiology of hepatitis B virus in Africa, its genotypes and clinical associations of genotypes","volume":"37","author":"Kramvis","year":"2007","journal-title":"Hepatol Res"},{"key":"10.1016\/j.lanmic.2025.101266_bib13","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/jmv.20311","article-title":"Increased hepatocarcinogenic potential of hepatitis B virus genotype A in Bantu-speaking sub-Saharan Africans","volume":"75","author":"Kew","year":"2005","journal-title":"J Med Virol"},{"key":"10.1016\/j.lanmic.2025.101266_bib14","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/jvh.13217","article-title":"Prevalence and burden of HBV co-infection among people living with HIV: a global systematic review and meta-analysis","volume":"27","author":"Platt","year":"2020","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.lanmic.2025.101266_bib15","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1038\/ajg.2015.289","article-title":"Hepatocellular carcinoma occurs at an earlier age in Africans, particularly in association with chronic hepatitis B","volume":"110","author":"Yang","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.lanmic.2025.101266_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2023.03.024","article-title":"Association between the presence of metabolic comorbidities and liver-related events in patients with chronic hepatitis B","volume":"21","author":"Patmore","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.lanmic.2025.101266_bib17","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1289\/ehp.0901388","article-title":"Global burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment","volume":"118","author":"Liu","year":"2010","journal-title":"Environ Health Perspect"},{"key":"10.1016\/j.lanmic.2025.101266_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fsufs.2023.1128540","article-title":"Quantitative assessment of aflatoxin exposure and hepatocellular carcinoma (HCC) risk associated with consumption of select Nigerian staple foods","volume":"7","author":"Wenndt","year":"2023","journal-title":"Front Sustain Food Syst"},{"key":"10.1016\/j.lanmic.2025.101266_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0004276","article-title":"The African Medicines Agency-a potential gamechanger that requires strategic focus","volume":"5","author":"Wairagkar","year":"2025","journal-title":"PLoS Glob Public Health"},{"key":"10.1016\/j.lanmic.2025.101266_bib20","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S0140-6736(24)02846-0","article-title":"The African Critical Illness Outcomes Study (ACIOS): a point prevalence study of critical illness in 22 nations in Africa","volume":"405","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.lanmic.2025.101266_bib21","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1200\/JOP.0824604","article-title":"Ensuring patient safety and scientific credibility in clinical trials","volume":"4","year":"2008","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.lanmic.2025.101266_bib22","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12992-015-0096-x","article-title":"Why is patient safety so hard in low-income countries? A qualitative study of healthcare workers' views in two African hospitals","volume":"11","author":"Aveling","year":"2015","journal-title":"Global Health"},{"key":"10.1016\/j.lanmic.2025.101266_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115420","article-title":"Estimating implementation and operational costs of an integrated tiered CD4 service including laboratory and point of care testing in a remote health district in South Africa","volume":"9","author":"Cassim","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.lanmic.2025.101266_bib24","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.afjem.2021.03.014","article-title":"Impact of structured basic life-support course on nurses' cardiopulmonary resuscitation knowledge and skills: experience of a paediatric department in low-resource country","volume":"11","author":"Umuhoza","year":"2021","journal-title":"Afr J Emerg Med"},{"key":"10.1016\/j.lanmic.2025.101266_bib25","article-title":"Barriers that prevent adults living with HBV infection from participating in clinical research: experience from South Africa","volume":"9","author":"Mofokeng","year":"2023","journal-title":"J Virus Erad"},{"key":"10.1016\/j.lanmic.2025.101266_bib26","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK-25-100052","article-title":"Practical guide to clinical trial accessibility: making trial participation a standard of care","volume":"45","author":"Ebrahimi","year":"2025","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.lanmic.2025.101266_bib27","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1053\/j.gastro.2007.11.036","article-title":"Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach","volume":"134","author":"Pawlotsky","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.lanmic.2025.101266_bib28","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3390\/jpbi2030013","article-title":"Frameworks for ethical conduct in clinical trials and health research in Africa","volume":"2","author":"R\u00e4go","year":"2025","journal-title":"J Pharm Biotech Ind"},{"key":"10.1016\/j.lanmic.2025.101266_bib29","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.3390\/cells9102233","article-title":"Point-of-care tests for hepatitis B: an overview","volume":"9","author":"Xiao","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.lanmic.2025.101266_bib30","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1080\/14737159.2022.2076595","article-title":"Clinical utility of the 'Determine HBsAg' point-of-care test for diagnosis of hepatitis b surface antigen in Africa","volume":"22","author":"Ceesay","year":"2022","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.lanmic.2025.101266_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.invent.2025.100862","article-title":"A culturally adapted mobile cognitive behavioral therapy for individuals with hepatitis B on depression, anxiety and stress: a pilot randomized controlled trial","volume":"41","author":"Lao","year":"2025","journal-title":"Internet Interv"},{"key":"10.1016\/j.lanmic.2025.101266_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph182111139","article-title":"Development and pilot testing of a smartphone-based self-care program for patients with chronic hepatitis B","volume":"18","author":"Jang","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.lanmic.2025.101266_bib33","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2021-006419","article-title":"Conducting clinical research in a resource-constrained setting: lessons from a longitudinal cohort study in The Gambia","volume":"6","author":"Imam","year":"2021","journal-title":"BMJ Glob Health"},{"key":"10.1016\/j.lanmic.2025.101266_bib34","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.jhep.2021.01.014","article-title":"The changing context of hepatitis D","volume":"74","author":"Rizzetto","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.lanmic.2025.101266_bib35","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1056\/NEJMra2212151","article-title":"Hepatitis D virus infection","volume":"389","author":"Asselah","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanmic.2025.101266_bib36","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1093\/infdis\/155.5.931","article-title":"Influence of hepatitis delta virus infection on progression to cirrhosis in chronic hepatitis type B","volume":"155","author":"Fattovich","year":"1987","journal-title":"J Infect Dis"},{"key":"10.1016\/j.lanmic.2025.101266_bib37","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/apt.15521","article-title":"Long-term clinical outcomes in patients with chronic hepatitis delta: the role of persistent viraemia","volume":"51","author":"Palom","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.lanmic.2025.101266_bib38","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.cgh.2020.05.041","article-title":"Association between seroclearance of hepatitis B surface antigen and long-term clinical outcomes of patients with chronic hepatitis B virus infection: systematic review and meta-analysis","volume":"19","author":"Anderson","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.lanmic.2025.101266_bib39","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1002\/hep.31214","article-title":"Long-term study of hepatitis delta virus infection at secondary care centers: the impact of viremia on liver-related outcomes","volume":"72","author":"Kamal","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.lanmic.2025.101266_bib40","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1111\/jvh.13577","article-title":"Risk of hepatocellular carcinoma in hepatitis B and D virus co-infected patients: a systematic review and meta-analysis of longitudinal studies","volume":"28","author":"Kamal","year":"2021","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.lanmic.2025.101266_bib41","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.3390\/v13101912","article-title":"Hepatitis D review: challenges for the resource-poor setting","volume":"13","author":"Lee","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.lanmic.2025.101266_bib42","article-title":"Hepatitis D epidemiology and access to diagnostic testing among healthcare providers in Africa: a multi-country survey","volume":"7","author":"Buti","year":"2025","journal-title":"JHEP Rep"},{"key":"10.1016\/j.lanmic.2025.101266_bib43","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa2213429","article-title":"A phase 3, randomized trial of bulevirtide in chronic hepatitis D","volume":"389","author":"Wedemeyer","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanmic.2025.101266_bib44","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/s41392-024-01871-8","article-title":"Optimized RNA interference therapeutics combined with interleukin-2 mRNA for treating hepatitis B virus infection","volume":"9","author":"Zai","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.lanmic.2025.101266_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtn.2017.04.019","article-title":"Nucleic acid polymers with accelerated plasma and tissue clearance for chronic hepatitis B therapy","volume":"8","author":"Roehl","year":"2017","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.lanmic.2025.101266_bib46","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.3390\/v13061090","article-title":"Review of lambda interferons in hepatitis B virus infection: outcomes and therapeutic strategies","volume":"13","author":"Novotny","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.lanmic.2025.101266_bib48","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S2468-1253(18)30270-X","article-title":"Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission","volume":"4","author":"Cooke","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.lanmic.2025.101266_bib49","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S2468-1253(25)00045-7","article-title":"Pathogens don't respect politicians: US federal disruption poses a new threat to global public health","volume":"10","author":"Wang","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.lanmic.2025.101266_bib51","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S2468-1253(23)00449-1","article-title":"Development and evaluation of a simple treatment eligibility score (HEPSANET) to decentralise hepatitis B care in Africa: a cross-sectional study","volume":"9","author":"Minier","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.lanmic.2025.101266_bib52","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1017\/S095026882300050X","article-title":"Hepatitis B in Africa Collaborative Network: cohort profile and analysis of baseline data","volume":"151","author":"Riches","year":"2023","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.lanmic.2025.101266_bib56","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1097\/HEP.0000000000000382","article-title":"Preventing 2 viral infections with 1 tablet","volume":"77","author":"Huang","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.lanmic.2025.101266_bib57","author":"Alcorn"},{"key":"10.1016\/j.lanmic.2025.101266_bib58","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/287269","article-title":"Rapid point-of-care testing for detection of HIV and clinical monitoring","volume":"2013","author":"Arora","year":"2013","journal-title":"ISRN AIDS"},{"key":"10.1016\/j.lanmic.2025.101266_bib60","author":"Mishra"},{"key":"10.1016\/j.lanmic.2025.101266_bib61","doi-asserted-by":"crossref","first-page":"7525","DOI":"10.1038\/s41467-025-62839-y","article-title":"Strengthening vaccine capacity building on the African continent","volume":"16","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.lanmic.2025.101266_bib62","doi-asserted-by":"crossref","first-page":"600","DOI":"10.3390\/microorganisms11030600","article-title":"Dynamics of hepatitis B virus covalently closed circular DNA: a mini-review","volume":"11","author":"Hu","year":"2023","journal-title":"Microorganisms"},{"key":"10.1016\/j.lanmic.2025.101266_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.coviro.2023.101360","article-title":"Hepatitis-B virus: replication cycle, targets, and antiviral approaches","volume":"63","author":"Nasser","year":"2023","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.lanmic.2025.101266_bib64","doi-asserted-by":"crossref","first-page":"331","DOI":"10.4254\/wjh.v16.i3.331","article-title":"Advances in discovery of novel investigational agents for functional cure of chronic hepatitis B: a comprehensive review of phases II and III therapeutic agents","volume":"16","author":"Lam","year":"2024","journal-title":"World J Hepatol"},{"key":"10.1016\/j.lanmic.2025.101266_bib65","doi-asserted-by":"crossref","first-page":"593","DOI":"10.5009\/gnl240023","article-title":"Toward a functional cure for hepatitis B","volume":"18","author":"Lok","year":"2024","journal-title":"Gut Liver"},{"key":"10.1016\/j.lanmic.2025.101266_bib66","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g4254","article-title":"Protections for clinical trials in low and middle income countries need strengthening not weakening","volume":"349","author":"Dal-R\u00e9","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.lanmic.2025.101266_bib67","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jacbts.2017.11.007","article-title":"Expanding patient access to investigational drugs: single patient investigational new drug and the \"right to try\"","volume":"3","author":"Van Norman","year":"2018","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.lanmic.2025.101266_bib68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15761\/JTS.1000467","article-title":"Attitudes towards clinical trial participation among people living with chronic hepatitis B","volume":"8","author":"Ibrahim","year":"2022","journal-title":"J Transl Sci"},{"key":"10.1016\/j.lanmic.2025.101266_bib69","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.cpcardiol.2018.11.002","article-title":"Increasing diversity in clinical trials: overcoming critical barriers","volume":"44","author":"Clark","year":"2019","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.lanmic.2025.101266_bib70","article-title":"Community dialogue to enhance understanding of beliefs, behaviours and barriers to care for people living with liver disease and HBV infection in KwaZulu Natal, South Africa","volume":"10","author":"Ngwenya","year":"2024","journal-title":"J Virus Erad"}],"container-title":["The Lancet Microbe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666524725001946?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666524725001946?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:57:17Z","timestamp":1790283437000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666524725001946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2666524725001946"],"URL":"https:\/\/doi.org\/10.1016\/j.lanmic.2025.101266","relation":{},"ISSN":["2666-5247"],"issn-type":[{"value":"2666-5247","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Strengthening hepatitis B virus clinical research in Africa: the need for multistakeholder collaboration, funding, and political will","name":"articletitle","label":"Article Title"},{"value":"The Lancet Microbe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanmic.2025.101266","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101266"}}